Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 17/20 | 0.58 |
| ▸ | NPY1R | P25929 | 11/20 | 0.58 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.58 |
| ▸ | NPY2R | P49146 | 7/20 | 0.58 |
| ▸ | CD40 | P25942 | 1/20 | 0.48 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30474555 | 0.94 | NPY4R (0.57) | NPY4RNPY1RNPY5RNPY2RCD40 | |
| SCHEMBL30666363 | 0.93 | NPY4R (0.66) | NPY4RNPY1RNPY5RNPY2RNAALAD2 | |
| SCHEMBL30558178 | 0.93 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2RCD40 | |
| SCHEMBL29558352 | 0.92 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31256982 | 0.91 | NPY4R (0.60) | NPY4RNPY1RNPY5RNPY2RCD40 | |
| SCHEMBL30516170 | 0.90 | NPY4R (0.56) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30335016 | 0.90 | NPY4R (0.58) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30411494 | 0.90 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2RCD40 | |
| SCHEMBL29895842 | 0.90 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29429181 | 0.90 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2RCD40 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260036586-A1 | DETECTION OF LARP1 | LTD PRENOSTICS (GB) | 2026-02-05 | — | — | US | disclosed |
| US-12352751-B2 | Detection of LARP1 | PRENOSTICS LIMITED | 2025-07-08 | — | — | US | disclosed |
| WO-2025093876-A1 | DETERMINATION OF OVARIAN CANCER STATUS BASED ON LARP1 AND CA125 EXPRESSION | RNA GUARDIAN LTD (GB) | 2025-05-08 | — | — | WO | disclosed |
| US-20220326247-A1 | DETECTION OF LARP1 | PRENOSTICS LIMITED (GB) | 2022-10-13 | — | — | US | disclosed |
| EP-4038390-A1 | DETECTION OF LARP1 | RNA Guardian Limited (GB) | 2022-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260036586-A1 | DETECTION OF LARP1 | IGF2BP3, IGF2BP1, LARP1 | NPY4R 1087/4885NPY1R 1395/4885NPY5R 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.